Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza

Journal of Virology

Volumn 70, Issue 9, 1996, Pages 6418-6424

  Bender, Bradley S ^a,b   Rowe, Cheryl A ^b   Taylor, Scott F ^a   Wyatt, Linda S ^c   Moss, Bernard ^c   Small Jr , Parker A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; INFLUENZA VACCINATION; INFLUENZA VIRUS; INTRAGASTRIC DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT;

EID: 0029836437     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.9.6418-6424.1996     Document Type: Article

References (73)

1. Andrew, M. E., and B. E. H. Coupar. 1988. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand. J. Immunol. 28:81-85.
2. Bell, W., P. A. Small, Jr., and B. S. Bender. Unpublished data.
3. Bender, B. S., W. E. Bell, and P. A. Small, Jr. 1994. Class I major histocompatibility complex-restricted cytotoxic T-lymphocytes are not necessary for heterotypic immunity to influenza. J. Infect. Dis. 170:1195-1200.
4. Bender, B. S., T. Croghan, L. Zhang, and P. A. Small, Jr. 1992. Transgenic mice lacking class I major histocompatibility complex-restricted T-cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 175:1143-1145.
5. Bender, B. S., M. P. Johnson, C. Flexner, B. Moss, and P. A. Small, Jr. 1990. Cytotoxic T-lymphocyte activity induced by influenza vaccination in young and aged mice, p. 69-73. In F. Brown, R. Chanock, H. S. Ginsberg, and R. A. Lerner (ed.), Vaccines 90. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
6. Bender, B. S., M. P. Johnson, and P. A. Small, Jr. 1991. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology 72:514-519.
7. Bender, B. S., and P. A. Small, Jr. 1993. Heterotypic immune mice lose protection against influenza infection in senescence. J. Infect. Dis. 168:873-880.
8. Bender, B. S., S. F. Taylor, D. Zander, and R. Cottey. 1995. Pulmonary immune response of young and aged mice following influenza challenge. J. Lab. Clin. Med. 126:169-177.
9. Bennink, J. R., J. W. Yewdell, G. L. Smith, C. Moller, and B. Moss. 1984. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature (London) 311:578-579.
10. Bennink, J. R., J. W. Yewdell, G. L. Smith, and B. Moss. 1987. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J. Virol. 61:1098-1102.
11. Blancou, J., M. P. Kieny, R. Lathe, J. P. Lecocq, P. P. Pastoret, J. P. Soulebot, and P. Desmettre. 1986. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature (London) 322:373-375.
12. Bloom, B. R. 1989. Vaccines for the third world. Nature (London) 342:115-120.
13. Brandtzeag, P. 1989. Overview of the mucosal immune system. Curr. Top. Microbiol. Immunol. 146:13-25.
14. Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti, and S. Plotkin. 1992. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339:1429-1432.
15. Centers for Disease Control. 1991. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Weekly Rep. 40(RR-14):1-10.
16. Clements, M. L., R. S. Betts, E. L. Tierney, and B. R. Murphy. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
17. Cross, R. M., C. Kaplan, and D. McClean. 1957. The heat resistance of dried smallpox vaccine. Lancet i:446-448.
18. Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P. C. Doherty. 1991. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174:875-880.
19. Epstein, S. L., C.-Y. Lo, J. A. Misplon, C. M. Lawson, B. R. Murphy, and E. K. Subbarao. 1995. Mediators of heterosubtypic immunity to influenza virus infection in mice, p. 393-397. In R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norling (ed.), Vaccines 95. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
20. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva.
21. Frank, A. L., L. H. Taber, and J. M. Wells. 1983. Individuals infected with two subtypes of influenza A virus in the same season. J. Infect. Dis. 147: 120-124.
22. Gammelin, M., J. Mandler, and C. Scholtissek. 1989. Two subtypes of nucleoproteins (NP) of influenza A viruses. Virology 170:71-80.
23. Ghendon, Y. 1989. The immune response of humans to live and inactivated influenza vaccines. Adv. Exp. Med. Biol. 257:37-45.
24. Gorman, O. T., W. J. Bean, Y. Kawaoka, I. Donatelli, Y. Guo, and R. G. Webster. 1991. Evolution of influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and classical swine viruses. J. Virol. 65:3704-3714.
25. Hochstein-Mintzel, V., H.-C. Huber, and H. Stickl. 1972. Die orale und nasale Immunisierung mit Poxvirus Vacciniae. III. Mitteilung: tierexperimentelle Untersuchungen. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. I Orig. B. 156:30-96.
26. Hochstein-Mintzel, V., H.-C. Huber, and H. Stickl. 1972. Virulenz und Immunogenität eines modifizierten Vaccinia-Virus (Stamm MVA). Z. Immununitaetsforsch. 144:140-145.
27. Jenner, E. 1798. An inquiry into the causes and effects of the variolac vaccinea. Sampson Low, London. (Reprint, Classics of Medicine Library, Birmingham, Ala., 1978.)
28. Kanesaki, T., B. R. Murphy, P. L. Collins, and P. L. Ogra. 1991. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J. Virol. 65:657-663.
29. Lawson, C. M., J. R. Bennink, N. P. Restifo, J. W. Yewdell, and B. R. Murphy. 1994. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A nucleoprotein peptide do not protect mice against challenge. J. Virol. 68:3505-3511.
30. Liang, S., K. Mozdzanowska, G. Palladino, and W. Gerhard. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
31. Lin, Y., and B. A. Askonas. 1981. Biological properties of an influenza A virus-specific cytotoxic T lymphocyte clone. J. Exp. Med. 154:225-234.
32. Lukacher, A. E., V. L. Braciale, and T. J. Braciale. 1984. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J. Exp. Med. 160:814-826.
33. Mayr, A., and K. Danner. 1979. Bedeutung von Tierpocken für den Menschen nach Aufhebung der Pflichtimpfung gegen Pocken. Berl. Mucnch. Tieraerztl. Wochenschr. 92:251-256.
34. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes. Infection 3:6-14.
35. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit per parenteralen Schutzimpfung and Verhalten im abwehrgeschwächten Organismus. Zentralbl. Bakteriol. Parasitenkd. Infektionskd. Hyg. Abt. I Orig. B 167:375-390.
36. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69:1339-1343.
37. Mazanec, M. B., C. S. Kaetzel, M. E. Lamm, D. Fletcher, and J. G. Nedrud. 1992. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl. Acad. Sci. USA 89:6901-6905.
38. McGhee, J. R., and J. Mestecky. 1990. In defense of mucosal surfaces. Infect. Dis. Clin. N. Am. 4:315-341.
39. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system. From fundamental concepts to vaccine development. Vaccine 10:75-88.
40. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Peare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
41. Meitin, C. A., B. S. Bender, and P. A. Small, Jr. 1991. Influenza immunization: intranasal immunization with a live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine 9:751-756.
42. Meitin, C. A., B. S. Bender, and P. A. Small, Jr. 1994. Enteric immunization of mice against influenza with recombinant vaccinia. Proc. Natl. Acad. Sci. USA 91:11187-11191.
43. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
44. Moss, B. 1991. Vaccinia virus: a tool for research and vaccine development. Science 252:1662-1667.
45. Nuchtern, J. G., J. G. Bonifacino, W. E. Biddison, and R. D. Klausner. 1989. Brefeldin A implicates egress from endoplasmic reticulum in class 1 restricted antigen presentation. Nature (London) 339:223-226.
46. Palladino, G., K. Mozdzanowska, G. Washko, and W. Gerhard. 1995. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69:2075-2081.
47. Paoletti, E., B. R. Lipinskas, C. Samsonoff, S. Mercer, and D. Panicali. 1984. Construction of live vaccines using genetically engineered posviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA 81:193-197.
48. Renegar, K. B., and P. A. Small, Jr. 1991. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:2146-2148.
49. Renegar, K. B., and P. A. Small, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972-1978.
50. Robbins, A., and P. Freeman. 1988. Obstacles for developing vaccines for the third world. Sci. Am. 259(5):126-133.
51. Rupprecht, C. E., and M. P. Kieny. 1988. Development of a vaccinia-rabies glycoprotein recombinant virus vaccine, p. 335-364. in J. B. Campbell and K. M. Charlton (ed.), Developments in veterinary virology series, vol. C. Rabies. Kluwer Academic Publishers, Boston.
52. Rupprecht, C. E., T. J. Wiktor, D. H. Johnston, A. M. Hamir, B. Dietzchold, W. H. Wunner, L. T. Glickman, and H. Koprowski. 1986. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA 83:7947-7950.
53. Scherle, P. A., G. Palladino, and W. Gerhard. 1992. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J. Immunol. 148:212-216.
54. Schulman, J. L., and E. D. Kilbourne. 1965. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J. Bactcriol. 89:170-174.
55. Small, P. A. 1990. Influenza: pathogenesis and host defense. Hosp. Pract. 25(11):51-62.
56. Small, P. A., Jr., G. L. Smith, and B. Moss. 1985. Intranasal vaccination with recombinant vaccinia containing influenza hemagglutinin prevents both influenza virus pneumonia and nasal infection: intradermal vaccination prevents only viral pneumonia, p. 175-176. In R. A. Lerner, R. M. Chanock, and F. Brown (ed.), Vaccines 85. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
57. Smith, G. L., B. R. Murphy, and B. Moss. 1983. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl. Acad. Sci. USA 80:7155-7159.
58. Sonoguchi, T., H. Naito, M. Hara, Y. Takeuchi, and H. Fukumi. 1985. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J. Infect. Dis. 151:81-88.
59. Steinhoff, M. C., L. F. Fries, R. A. Karron, M. L. Clements, and B. F. Murphy. 1993. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J. Clin. Microbiol. 31:836-838.
60. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schafer, and A. Holzner. 1974. MVA-Stufenimpfung gegen Pocken. Dtsch. Med. Wochenschr. 99:2386-2392.
61. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
62. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink. and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity to influenza virus. Vaccine 12:1032-1040.
63. Taylor, S. F., P. A. Small, Jr., and B. S. Bender. Unpublished observations.
64. Townsend, A., C. Öhlen, J. Basten, H.-G. Ljunggren, L. Foster, and K. Kärre. 1989. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (London) 340:443-448.
65. Townsend, A. R. M., A. J. McMichael, N. P. Carter, J. A. Huddleston, and G. G. Brownlee. 1984. Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell 9:13-25.
66. Wells, M. A., F. A. Ennis, and P. Albrecht. 1981. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J. Immunol. 126:1042-1046.
67. Werner, G. T., U. Jentsch, E. Metzger, and J. Simon. 1980. Studies on poxvirus infection in irradiated animals. Arch. Virol. 64:247-256.
68. World Bank. 1993. Investing in health. Oxford University Press, London.
69. Yap, K., L. G. L. Ada, and I. F. C. McKenzie. 1978. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature (London) 273:238-241.
70. Yetter, R. A., S. Lehrer, R. Ramphal, and P. A. Small, Jr. 1980. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 29:654-662.
71. Yewdell, J. W., J. R. Bennink, and Y. Hosaka. 1988. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239:637-640.
72. Yewdell, J. W., J. R. Bennink, G. L. Smith, and B. Moss. 1985. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82:1785-1789.
73. Yilma, T., D. Hsu, L. Jones, S. Owens, M. Grubman, C. Mebus, M. Yamanaka, and B. Dale. 1988. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 242:1058-1061.